On October 15, Aehr Test fell 8.14% in Regular Trading, trading at $71.14, with turnover of $112 million.
The move coincided with renewed market concern that Teradyne's newly announced Titan HP could intensify competition in semiconductor test and burn-in equipment, prompting a repricing of Aehr Test shares.
Recent developments show Aehr Test has still been booking follow-on demand, including a roughly $22 million wafer-level AI processor order in August, an approximately $6 million AI chip testing equipment order in October, and continued silicon photonics expansion orders. Separately, Oppenheimer said the post-Titan HP selloff appeared overdone and described the weakness as a buying opportunity, indicating that the latest decline reflects competitive worries more than a deterioration in disclosed order momentum.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments